A Phase 2 interventional study of NXL103 and comparator in Community Acquired Pneumonia, sponsored by Novexel Inc. Completed at 60 sites in 9 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-01-09.
Sponsored by Novexel Inc · Phase 2, Interventional, and Treatment
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's enrollment of 302 is above the median of 106 across 1,247 interventional studies indexed under Pneumonia.
Browse Pneumonia studies →Novexel Inc is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
NXL103
Drug: NXL103
Drug: comparator
NXL103
Drug: NXL103
600mg orally twice daily
comparator twice daily
500mg orally twice daily
Evaluate Clinical outcome
Time frame: early follow up visit (day 14 to 21)
Evaluate bacteriological outcome
Time frame: early follow up visit (day 14 to 21)
Evaluate safety
Time frame: first dose, throughout treatment, and to follow up visit
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novexel Inc